<code id='4CA20BCFBF'></code><style id='4CA20BCFBF'></style>
    • <acronym id='4CA20BCFBF'></acronym>
      <center id='4CA20BCFBF'><center id='4CA20BCFBF'><tfoot id='4CA20BCFBF'></tfoot></center><abbr id='4CA20BCFBF'><dir id='4CA20BCFBF'><tfoot id='4CA20BCFBF'></tfoot><noframes id='4CA20BCFBF'>

    • <optgroup id='4CA20BCFBF'><strike id='4CA20BCFBF'><sup id='4CA20BCFBF'></sup></strike><code id='4CA20BCFBF'></code></optgroup>
        1. <b id='4CA20BCFBF'><label id='4CA20BCFBF'><select id='4CA20BCFBF'><dt id='4CA20BCFBF'><span id='4CA20BCFBF'></span></dt></select></label></b><u id='4CA20BCFBF'></u>
          <i id='4CA20BCFBF'><strike id='4CA20BCFBF'><tt id='4CA20BCFBF'><pre id='4CA20BCFBF'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:Wikipedia    Page View:5
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In